Intranasal delivery of neutralizing antibodies for prophylatic COVID-19 treatments

鼻内递送中和抗体用于预防性 COVID-19 治疗

• 批准号: 555162-2020
• 负责人: Wylie, Ryan
• 金额: $ 3.64万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=705603
• 关键词: Intranasal; delivery; neutralizing; antibodies; prophylatic

Technologies for passive immunity have the potential to decrease the transmission of SARS-CoV-2 in our communities and high-risk environments such as long term care homes. The intranasal delivery of virus neutralizing antibodies prior or soon after exposure to SARS-CoV-2 can prevent infection, which is a form of passive immunity. Therefore, intranasal delivery of neutralizing antibodies can prevent exposed individuals from getting sick and prevent the spread of disease. Passive immunity therapies are required as an alternative to vaccines, which may take multiple years to develop and fully implement. Furthermore, high risk populations such as the elderly have poor vaccine response rates, limiting their effectiveness. To this end, we are developing delivery technologies to sustain the delivery of neutralizing antibodies for SARS-CoV-2 that can be administered through a simple nasal spray. Our goal is to decrease virus transmission in the community, which will allow for a greater quality of life and potentially eliminate the need for lockdowns.

被动免疫技术有可能减少SARS-CoV-2在我们的社区和高风险环境（如长期护理院）中的传播。在暴露于SARS-CoV-2之前或之后不久通过鼻内递送病毒中和抗体可以预防感染，这是一种被动免疫形式。因此，中和抗体的鼻内递送可以防止暴露个体生病并防止疾病传播。需要被动免疫疗法作为疫苗的替代品，这可能需要多年的时间来开发和全面实施。此外，高风险人群如老年人的疫苗应答率很低，限制了它们的有效性。 为此，我们正在开发递送技术，以持续递送SARS-CoV-2的中和抗体，这种抗体可以通过简单的鼻喷雾剂给药。我们的目标是减少病毒在社区中的传播，这将提高生活质量，并可能消除封锁的必要性。